Castañeda-Castañeda DF, Morales-Villarreal MA

Language: Spanish
References: 10
Page: 124-127
PDF size: 512.56 Kb.

ABSTRACT

A 46-years-old female, with a diagnosis of infection by Human Immunodeficiency Virus (HIV) in 1999, displays virologic failure in 2005 initiating scheme with emtricitabine/tenofovir + darunavir/ritonavir, achieving virological suppression and immunologic reconstitution. In May of 2008 presents memory alteration, walk deviation, dysarthria, VI pair cranial complain and central origin facial paralysis, dysdiadochokinesia, and difficulty to hold objects with left hand. A Cranium Magnetic Resonance Imaging (MRI) with gadolinium was done, where lesions on cerebral sub-cortical nodes, perilesional edema and periventricular demyelinating are observed. The viral panel on cerebrospinal fluid and serum tested positive for parvovirus B19 (BP19). It is associated with late immune reconstitution inflammatory syndrome (IRIS) secondary to infection by BP19, therefore 3 immunoglobulin intravenous therapy cycles are received, subsiding the symptomatology gradually. The BP19 is a virus of single chain DNA. Two ways of presentation of infection by BP19 on patients with HIV have been described, one as exantematic disease on patients with HIV without AIDS and another on patients with HIV/AIDS as a persistent infection and chronic viremia, causing transitory inhibition of the erythropoiesis. It has been reported cases with neurological manifestations such as encephalitis, meningitis, cerebrovascular accident, peripheral neuropathy and epileptic status. Moreover, it is commonly associated to chronic fatigue syndrome.

REFERENCES

1. Heegaard ED, Brown KE. Human parvovirus B19. Clin Microbiol Rev 2002; 15:485–505.

2. Kerr JR. Pathogenesis of Parvovirus B19 Infection: Host Gene Variability, and Possible Means and Effects of Virus Persistence. J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):335-9.

3. Setúbal S, Jorge-Pereira MC, de Sant'Anna AL, de Oliveira SA, Bazin AR, do Nascimento JP. Clinical presentation of parvovirus B19 infection in HIVinfected patients with and without AIDS. Rev Soc Bras Med Trop. 2003 Mar-Apr;36(2):299-302. Epub 2003 Jun 10.

4. Douvoyiannis M, Litman N, Goldman DL. Neurologic Manifestations Associated with ParvovirusB19 Infection. Clin Infect Dis. 2009 Jun 15;48(12):1713-23.

5. Okumura A, Ichikawa T. Aseptic meningitis caused by human parvovirus B 19. Arch Dis Child. 1993 Jun;68(6):784-5.

6. Druschky K, Walloch J, Heckmann J, Schmidt B, Stefan H, Neundörfer B. Chronic parvovirus B-19 meningoencephalitis with additional detection of Epstein-Barr virus DNA in the cerebrospinal Fluid of an immunocompetent patient. J Neurovirol. 2000 Oct;6(5):418-22.

7. Skaff PT, Labiner DM. Labiner, Status epilepticus due to human parvovirus B19 encephalitis in an immunocompetent adult, Neurology. 2001 Oct 9;57(7):1336-7.

8. Clarke J, Lee JD. Primary human parvovirus B19 infection in an HIV infected patient on highly active antiretroviral therapy, Sex Transm Infect. 2003 Aug;79(4):336.

9. Nolan RC, Chidlow G, French MA. Parvovirus B19 Encephalitis Presenting as Immune Restoration Disease after Highly Active Antiretroviral Therapy for Human Immunodeficiency Virus Infection. Clin Infect Dis. 2003 May 1;36(9):1191-4. Epub 2003 Apr 14.

10. Young NS, Brown KE. Parvovirus B19, N Engl J Med. 2004 Feb 5;350(6):586-97.